Eligibility for adjuvant PARPi treatment typically includes patients who have a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants and have high-risk, HER2-negative primary BC after definitive local treatment and neoadjuvant or adjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.